Pharma Sector

Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins

Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.

Emcure Pharma Q2FY27 net profit rises 34% to ₹325.5 crore, revenue up 24%

Emcure Pharmaceuticals reports 24.2 per cent revenue growth in Q2FY27, led by strong international sales, while domestic business expands 12 per cent and net profit rises 33.7 per cent

Centre proposes expanding import gateways for drugs, medical devices

The Union Health Ministry has proposed expanding the network of authorised import gateways for drugs, medical devices and cosmetics by adding several inland container depots, a special economic zone and an international airport to facilitate faster clearance and improve supply chain efficiency. The proposed amendment to Rule 43A of the Drugs Rules, 1945, seeks to include additional entry points in Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka, according to a gazette notification issued by the ministry. The proposed locations include Inland Container Depots (ICDs) at Sonipat, Piyala and Harsaru in Haryana; Dadri in Uttar Pradesh; Gandhidham/Mundra in Gujarat; Sanath Nagar and Thimmapur in Hyderabad; and Whitefield in Bengaluru. The ministry has also proposed including the Bommasandra Special Economic Zone (SEZ) in Karnataka and Noida International Airport in Uttar Pradesh for the import of drugs by air. Rule 43A specifies the authorised ports, airports, railway stations,

Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades

Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.

RPG Life Sciences eyes another acquisition with ₹500 crore capital pool

The drugmaker plans to deploy ₹500 crore for another acquisition within 12 months as it targets 25 per cent annual growth in its API business over the next five years

ERP transformation key to ensuring pharma manufacturing continuity: Experts

Modernising pharma through enterprise resource planning (ERP) transformation replaces vulnerable legacy systems with a single source of truth, ensuring uninterrupted manufacturing continuity, according to experts. "This digital evolution gives life sciences companies the agility and data integrity needed to seamlessly meet strict regulatory requirements," Mandar Ghatnekar, Chief Technology Officer, Biocon, said while addressing the 15th edition of the Pharma IT Summit Mumbai 2026 organised by Exito Media Concepts earlier in the week. Speakers from top pharmaceutical companies, who attended the summit, also advocated for the need for human review of GenAI outputs, particularly in a good practice (GxP) environment. "In a highly regulated industry like pharmaceuticals, successful AI adoption requires a strong foundation of people, process, technology and governance, balancing innovation with regulatory compliance and operational excellence. "The future of AI will be defined not by how

India's pharma exports grow 4.9% to $16.14 bn in H1FY27 on Europe gains

India's pharmaceutical exports rose 4.9 per cent to $16.14 billion in H1FY27, driven by growth in Europe, ASEAN and Latin America, even as shipments to the US moderated.

India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report

India's pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, as private equity activity surged and public market fundraising gained momentum.

Centre cuts MRPs for trade-margin-capped cancer meds by up to 93%

Major innovator brands see no price reductions despite cuts of up to 93 per cent for some cancer medicines; patient groups say PAP exclusions and data gaps have diluted relief

Dr Reddy's net profit down 36% on lower Revlimid sales in North America

The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth

Centre forms 3-member panel to review pharma marketing code, enforcement

The three-member committee will assess the effectiveness of the UCPMP, examine enforcement mechanisms and recommend measures to curb unethical pharmaceutical marketing practices

Torrent Pharma Q2 profit falls 9.6% to ₹534 crore, revenue rises 51%

Torrent Pharma's Q2FY27 net profit declined 9.6 per cent to ₹534 crore despite a 50.8 per cent rise in revenue, as higher finance costs and depreciation weighed on earnings

GLP-1 boom in India, China, Brazil can create $22 bn market: JP Morgan

The addressable ​market could grow at an annual rate of 15% through 2035, JP Morgan ‌analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens

CDMO players bet on complex products such as biologics, peptides for growth

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

Sun Pharma accepts bids worth ₹7,816 crore for two five-year bonds

Sun Pharma has accepted bids worth ₹7,816 crore for two bond tranches maturing in five years and one day, offering annual coupons of 8.05% and 8.20%, merchant bankers said.

Back to front? Green shoots in defensive sectors signal potential recovery

Weak demand, AI-led growth concerns and US export headwinds weigh on defensive stocks, while valuation moderation signals potential opportunities

Semaglutide mkt settles into steady growth six months after patent expiry

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

Supreme Court asks Centre to frame statutory rules for pharma marketing

The Supreme Court has directed the Centre to constitute a committee to examine statutory regulations on pharmaceutical marketing, including gifts and incentives offered to doctors

Trump's 100% pharma tariff kicks in today, select Indian drugs get relief

Specified speciality drugs from India and 19 other jurisdictions qualify for zero duty as the US extends its 100% pharma tariff to more companies; generics remain outside its scope

MSD appoints Vidhya Sundaram as Associate VP of Global Technology Centres

Pharmaceutical company MSD on Monday said it has appointed Vidhya Sundaram as Associate Vice President, Global Technology Centers, and Hyderabad Tech Center Lead. Vidhya, based in Hyderabad, will oversee MSD's global Technology Center strategy, working closely with global technology leaders to deepen collaboration across locations and support business outcomes, a company statement said. She will also lead the Hyderabad Tech Center, helping advance the digital capabilities that support MSD's work to deliver innovative solutions for human and animal health around the world. MSD, which operates as Merck & Co., Inc in the US and Canada markets, recently inaugurated the Tech Centre's expanded workplace in Hyderabad. Vidhya brings more than 20 years of experience building and scaling global capability organisations and driving business outcomes through digital and technology across the life sciences industry, the company said. Prior to joining MSD, Vidhya held leadership roles at Eli ...